NCT00689598

Spironolactone for Paroxysmal Atrial Fibrillation

Use of Spironolactone to Treat Patients With Paroxysmal Atrial Fibrillation- A Multi-Center, Prospective, Randomized, Placebo-Controlled, Double Blind Study

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Taichung Veterans General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To determine whether or not spironolactone can prevent or delay the occurrence of atrial fibrillation.

Detailed description

To determine whether or not adding spironolactone can prevent or delay the occurrence of paroxysmal atrial fibrillation in patients who have received propafenone treatment.

Conditions

• Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	Spironolactone	25 mg po qd 25 mg po bid
DRUG	Placebo	Spironolactone 25 mg po qd

Timeline

• Start date: 2008-03-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2008-06-03
• Last updated: 2008-06-05

Locations

1 site across 1 country: Taiwan